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I. Introduction  
 
Achieving efficient pricing of pharmaceuticals between and within countries is a complex 
conceptual and policy problem. In any industry, pricing to maximize social welfare must 
consider both static efficiency (optimal use of existing products) and dynamic efficiency 
(optimal investment in R&D). Reconciling these objectives is problematic for pharmaceuticals, 
for three reasons.  
First, R&D is roughly 17 percent of sales for the US-based pharmaceutical industry, 
compared to 4 percent for other US industries, and other quasi-fixed costs of production are 
significant.  Marginal cost pricing to achieve first best static efficiency would fail to cover total 
costs and would violate the dynamic efficiency requirement, that producers capture the full social 
surplus produced by innovation. Patents enable firms to price above marginal cost and thus 
potentially achieve dynamic efficiency. This would be “second best” to the extent that pricing 
above marginal cost reduces utilization.  
Second, in the case of pharmaceuticals the effect of patents is both mitigated and 
distorted by insurance coverage.  Most industrialized countries have universal coverage with 
modest patient co-payments. By lowering out-of-pocket prices to patients, insurance potentially 
brings utilization closer to first best optimal levels. It also protects consumers from financial risk 
and, through cross-subsidies, makes health services more affordable to low-income consumers. 
However, because such insurance makes patient demand highly price-inelastic, insurance creates 
the potential and incentives for manufacturer prices that exceed the level that would result from 
patents alone.  Public and private insurers use various price control strategies to constrain this 
producer moral hazard but these controls are generally ad hoc and not designed to achieve static 
and dynamic efficiency. By contrast, many middle and lower income countries (MLICs) lack 
comprehensive insurance. Patients in such self-pay markets lack the financial protection of 
insurance but also avoid its distorting effects on prices. However, other factors – including 
uncertain product quality and skewed income distributions -- contribute to higher drug prices 
than might occur in well-functioning markets [1, 2].  
Third, because R&D is a global joint cost benefiting consumers worldwide, efficient 
global pricing requires appropriate contributions from different countries to this joint cost. 
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Economic theory suggests that price discrimination across countries is welfare superior to 
uniform pricing if price discrimination increases drug utilization, which is plausible given 
income differences. Ramsey pricing theory also supports differential pricing across countries, as 
the second best efficient way to recoup R&D cost, assuming that demand elasticities differ 
across countries. However, both price discrimination and Ramsey pricing theories give criteria 
for an efficient structure of relative prices but do not address optimal absolute price levels or 
suggest a practical strategy for implementation.  
This paper develops a framework of analysis and assumptions designed to achieve 
efficient absolute and relative prices between and within countries for pharmaceuticals. Although 
the focus here is on pharmaceuticals, the framework could be applied to other health 
technologies. The challenges and appropriate solutions in pharmaceutical pricing differ, 
depending on whether a country has comprehensive insurance. We therefore contrast two 
different insurance contexts: first, a market with universal coverage (relevant to most 
industrialized countries) and second, a predominantly self-pay market, where consumers pay 
cash out-of-pocket  for drugs (relevant to many MLICs). We call the set of efficient prices that 
result from our framework “value-based differential pricing.” The UK Office of Fair Trading use 
of the term “value-based pricing” to describe a “system that would relate the prices of products 
to their clinical value relative to existing treatments”[21]. We extend this concept by designing 
an approach to not only relate prices to value but also maximize health gain from a given budget 
in each country and achieve static and dynamic efficiency globally.  
In countries with comprehensive insurance, pharmaceutical pricing is complicated by 
potential supplier and consumer moral hazard. In this context, we show that, given certain 
assumptions, second best optimal prices and utilization can be achieved if each payer or country 
defines an incremental cost effectiveness ratio (ICER) threshold that reflects its citizens’ 
willingness to pay for health gain, and pays for drugs that meet this value-for-money standard. 
These ICERs may differ by payer and/or drug or patient type (e.g. drugs for rare diseases or 
terminal medical conditions). We assume that manufacturers can set their prices freely, albeit 
constrained by their drug’s incremental effectiveness relative to the comparator current 
treatment. We assume that payers limit reimbursement to patients for whom the drug is cost-
effective at the manufacturer’s chosen price, in which case utilization will be second best 
optimal. If each country unilaterally sets its ICER threshold(s) to reflect its willingness-to-pay 
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for health gain, manufacturer price levels will differ appropriately across countries, and 
aggregate global revenues will create appropriate incentives for R&D. The ICER thresholds and 
resulting price levels can be expected to vary across countries in positive relation to per capita 
income, but the optimal relationship – prices varying more or less than in proportion to income – 
cannot be determined a priori.  
Self-pay countries without comprehensive insurance (many MLICs) avoid the distorting 
effects of insurance on manufacturer pricing, but also forego the insurance benefits of assuring 
financial protection and affordability of appropriate drugs for patients. Efficient pricing in self-
pay markets requires that: regulatory systems assure that all drugs, including for generic copies, 
meet specified quality standards; consumers or their agents are reasonably informed about drug 
quality and prices; and manufacturers can price-discriminate within countries that have highly 
skewed income distributions. In practice, these conditions are not met in many MLICs, leading 
to pricing above marginal cost and static efficiency loss that potentially outweighs the 
contribution of high prices to profits and dynamic efficiency [1, 2].  
Previous literature has addressed components of a theory of efficient drug pricing within 
a single country [3–7] and efficient price differentials across countries [8-12]. We contribute to 
this literature by outlining a comprehensive approach to simultaneously address within-country 
absolute price levels and between-country relative prices, distinguishing insured vs. self-pay 
markets. Our analysis is relevant for drugs that treat global diseases. It does not address 
“neglected disease” drugs, for which global demand is insufficient to incentivize private R&D. 
In the remainder of this paper, section II reviews previous literature; section III develops the 
value-based differential pricing (VBDP) model for countries with comprehensive insurance; 
section IV considers self-pay countries; section V discusses how VBDP differs from Ramsey 
pricing; section VI concludes. 
 
II. Previous Literature  
Optimal Use of Medical Care, No Insurance, Exogenous Prices and Technologies  
Garber and Phelps (GP) [3] develop a model of an uninsured individual’s optimal 
allocation of a fixed budget between medical care and other services, treating the availability and 
price of medical technologies as exogenous. At the optimum, the patient uses each medical 
service such that its ICER is equal to the patient’s marginal benefit in terms of expected future 
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utility normalized by the current marginal utility of income, or willingness-to-pay. GP briefly 
discuss the application of this model to third party payers, but do not address how a payer might 
use it. We extend the model to the context of a payer seeking to optimally constrain prices and 
utilization when faced with price-insensitive patients but endogenous prices and R&D.  
` 
Using Insurance to Achieve Static and Dynamic Efficiency in a Single Country  
A series of papers [4-5, 7] propose using a standard insurance two-part pricing structure 
of consumer co-payment and payer top-up payment to reconcile static and dynamic efficiency in 
a single country. To achieve static efficiency, they set co-payments equal to marginal cost and 
assume that consumers choose first best utilization. Payers pay top-up payments to transfer the 
social surplus to manufacturers, as required for dynamic efficiency. 
Garber et al. [4] examine the optimal coinsurance rate and incentives for innovation when 
a monopoly firm pursues profit maximizing pricing. Lowering the coinsurance rate encourages 
utilization, but also makes demand more inelastic and hence leads firms to charge higher prices. 
They show that with an unconstrained monopoly price, the optimal coinsurance rate for static 
efficiency may result in monopoly profits exceeding consumer surplus. They conclude that limits 
on monopoly pricing may be necessary to avoid excessive incentives for innovation, but do not 
discuss how to set such price limits.  
Lakdawalla and Sood (LS ) [ 7] argue that subsidized but optional public drug insurance 
with unregulated manufacturer prices, consumer choice of drugs, and a parallel uninsured 
market, can in theory achieve both static and dynamic efficiency. In their model, static efficiency 
is  achieved in the public program by setting the consumer co-payment equal to the 
manufacturer’s marginal cost. To achieve dynamic efficiency, the insurer tops up this co-
payment to the price the manufacturer charges to uninsured consumers. To deter a manufacturer 
from pricing above the uninsured monopoly pm, the public payer structures co-payments such 
that a $1 price increase above pm increases the co-payment by more than a $1. They note that in 
practice the public payer might constrain manufacturer price below pm to achieve short run 
savings, but that this would undermine dynamic efficiency.   
This model offers a theoretically elegant solution, but several key components are 
problematic. First, defining marginal cost in an industry with multiple fixed and quasi-fixed costs 
poses conceptual ambiguities, specifically, whether the co-payment should reflect just the 
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(usually minimal) incremental cost of one more dose, or also include an allocated share of quasi-
fixed/joint costs of plant capacity and country-specific overhead other than R&D. Further, 
models of optimal drug co-payments should also consider effects on use of substitute and 
complementary medical services, notably physician and hospital services [14]. Second, with 
universal public or social insurance, as exists in most industrialized countries, there is no 
uninsured monopoly price pm which the payer can use to benchmark top up payments. Even in 
countries like the US with an observable price to uninsured patients, this does not necessarily 
reflect the theoretically ideal monopoly price pm. In the US, for example, the price manufacturers 
charge to uninsured patients plausibly exceeds pm because this uninsured price is used by private 
and public insurers as the starting point for setting discounts and rebates, which creates 
incentives to raise pm. Third, LS assume that raising funds to subsidize public insurance is 
costless. If taxation in fact entails significant deadweight loss (see, for example, [13]), such that 
paying top-up payments to manufacturers is not a costless transfer, aiming for second best 
utilization and top-up payments may be preferable to first best.  
Jena and Phillipson (JP) [5] discuss the theoretical relationship between average endogenous 
cost-effectiveness, consumer and producer surplus and incentives for innovation. They assume 
that manufacturer pricing is driven by a consumer demand schedule that reflects patients’ true 
marginal benefit, regardless of their insurance coverage. Thus if payers use an ICER threshold as 
a condition of reimbursement, manufacturers adapt their prices to meet the threshold. JP show 
that a reduction in price that increases utilization may increase static efficiency but decrease the 
ex post, average endogenous cost-effectiveness ratio, if the additional users have lower 
incremental benefit.  They do not consider how payers might use an exogenously determined 
ICER threshold to achieve dynamic efficiency.  
 
Optimal price differentials across countries 
 Price discrimination Several papers model the welfare implications of price 
discrimination vs. uniform pricing across countries. Under plausible assumptions about demand 
dispersion across countries, profit-maximizing price discrimination that leads to prices inversely 
related to demand elasticities yields higher utilization and improves static efficiency compared to 
uniform pricing [8]. If R&D is endogenous, price discrimination plausibly also leads to higher 
R&D investment than uniform pricing [12, 15]. Effects of insurance are not addressed.  
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Ramsey Pricing  Ramsey pricing provides a theoretical foundation for second-best 
pricing to maximize social welfare, subject to meeting a revenue constraint to cover joint fixed 
costs [16-18]. Several papers [9-11] apply this theory of Ramsey optimal pricing (ROP) to 
consider how drug prices should vary across countries to maximize static efficiency, subject to 
covering the costs of R&D.  Because ROP prices vary inversely with demand elasticity, prices 
would vary be inversely related to per capita income across countries if true demand elasticities 
(before insurance) vary inversely with per capita income. Under certain conditions with respect 
to competitive entry and separable markets, the price differentials that an unregulated profit-
maximizing manufacturer would set voluntarily would be Ramsey optimal [9,10]. Optimal price 
differentials might exceed ROP differentials if high income countries have altruistic concerns for 
low income countries [11]. If a global regulator implements ROP, the effect of insurance in one 
or more markets on prices in those markets is ambiguous. Insurance makes demand less elastic, 
leading to higher prices in insured markets, but this may be offset if insurance increases 
manufacturer revenues such that all prices are reduced to satisfy the ROP revenue constraint 
[19].  
 
None of these models of price differentials between countries consider optimal absolute 
price levels or within-country price differentials. In this paper we extend this literature by 
developing a framework to achieve optimal absolute price levels in each country and optimal 
differentials between countries. By optimal, we mean that, subject to specified assumptions, 
including that patents are optimally set, social welfare is maximized in the sense of both static 
and dynamic efficiency. Our basic framework is designed to deliver “second best” solutions, 
which we argue may be more realistic and appropriate than models that aim for first best 
efficiency. Our proposed approach differs between countries with and without comprehensive 
insurance, because insurance fundamentally changes the challenges to efficiency in 
pharmaceutical markets and therefore changes appropriate solutions.   
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III. Value-Based Differential Pricing: A. Countries with Comprehensive Insurance  
 
Optimal ICER Threshold for a Representative Consumer: Exogenous Prices and Technology  
Assume that each country can be represented by an individual with income Y that is 
constant in real terms across time periods. Following Garber-Phelps (GP), period-specific utility 
of income as viewed from period 0 is ݒ	 ൌ 	ܷ଴ሺܻሻ, before discounting or quality of life 
adjustment. Income is spent on medical care technologies a and b, with prices ݓ௔ and ݓ௕   
respectively, which for now are assumed to be exogenously set, and on other goods. 
Consumption of medical care in period 0 can affect probability of survival ܲ and quality of life ݍ 
in future periods. Future utility is discounted by a factor ߩ. The expected benefits of medical care 
can thus be expressed as the sum of discounted expected future QALYs. Expected utility in 
period 0 can be written:  
     
E଴ 	ൌ 	ܷ଴ሺY	–	ݓ௔a	–	ݓ௕bሻ ൅ 	v෍ ሾρ௜ ݅	ݍ௜ 	ෑ ௝ܲሿ							ሺ1ሻ 
 
The optimal utilization of technology a using eq.1 is defined by the first order condition: 
 
െݓ௔ܷ଴ᇱ 	ൌ 	ݒ	 ݀ܳ݀ܽ 																				ሺ2ሻ 
 
In this framework, optimal utilization thus implies equating the marginal utility cost of spending 
on ܽ in period 0, ݓ௔ܷ଴ᇱ , to the marginal expected benefit, in terms of utility of future QALYs 
gained from using ܽ, ݒ	 ݀ܳ ݀ܽ⁄ . Rewriting: 
 	
ݓ௔
൭݀ܳ ݀ܽൗ ൱
ൌ 	 ݒܷ଴ᇱ 																				ሺ3ሻ 
        
The left hand side of eq. 3 is the ICER. The numerator is the incremental cost of using a, 
which here is just ݓ௔.  If use of a affects other medical costs (ca ) due to complementarity or 
substitution, incremental cost of a  would include these incremental costs or cost offsets. The 
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denominator is the expected QALYs gained from using a. Using this approach, at optimal 
utilization, the ICER is equal to the ratio of future, period-specific utility v to marginal utility in 
the base period, or willingness-to-pay for medical care.  
 
Application to a Universal Payer: Endogenous Prices and Utilization   
Assume that each country operates a universal insurance system including drugs for all 
citizens, to provide financial protection and reduce the effect of within-country income 
dispersion on access to medical care. The analysis can still focus on the representative consumer. 
Prices charged by manufacturers and technology availability are now endogenous and influenced 
by the design of the insurance. Reasonable financial protection for patients requires that cost-
sharing is modest and capped per patient. Manufacturers therefore face relatively inelastic 
demand which, in the absence of constraints, would lead to prices above the patent-induced level 
without insurance (supplier moral hazard). Assume that raising funds is costly, and hence that the 
payer seeks to achieve second best static and dynamic efficiency.  
In this context, eq. 3 implies that the payer can indirectly control prices by setting an 
ICER threshold K (e.g. ₤30,000 per QALY) that reflects its citizens’ willingness-to-pay for 
medical care:   
	ܫܥܧܴ ൌ 	 ሺݓ௔ െ ݓ଴ሻ ൅ ሺܿ௔ െ ܿ଴ሻ݀ܳ 		൑ ܭ																		ሺ3′ሻ 
 
If we assume a manufacturer is permitted to price	freely, subject to this constraint, it 
would set its price differential over current treatment at the highest level consistent with still 
meeting the ICER threshold, given the product’s incremental cost offsets and effectiveness gain:   
ݓ௔ ൌ ݓ଴ ൅ ݀ܿ ൅ ܭ݀ܳ																	ሺ3′′ሻ 
Thus a new product with no incremental benefit would be constrained to price at ݓ௢. A 
more effective product or one that substitutes for other services could be priced higher and still 
meet the ICER threshold. The payer’s ICER threshold acts as an indirect control on price, given 
the product’s incremental effectiveness and cost offsets.  
Given the manufacturer’s choice of price, the payer can achieve appropriate use by 
limiting coverage to those patients for whom the product is cost-effective at this price and ICER 
threshold. In the simplest case of a product for a single indication and uniform effects, all 
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patients with that condition would be treated. For more complex products, there may be a 
distribution of effectiveness across patient subgroups with different indications or severities. If 
the firm chooses a high price, the payer would restrict use to patients whose condition/indication 
implies an expected health benefit sufficient to meet the ICER threshold, whereas if the firm 
chooses a lower price, the payer can encourage use by patient subgroups with lower expected 
benefit and still meet the ICER threshold. Thus given the payer’s ICER threshold and a 
distribution of effectiveness across patients, the firm faces a price-volume trade-off similar to a 
demand curve except that the payer determines which uses will be reimbursed, given the price 
set by the manufacturer. If the firm can charge only one price, it would select the price yielding 
the highest expected profit, given the use that the payer would permit at that price.  This outcome 
would be second best efficient. But if effectiveness differs across indications/subgroups, then 
both static and dynamic efficiency could be enhanced and, at the limit, would be first best, if the 
firm could vary prices by indication/subgroup, reflecting the drug’s differential effectiveness and 
the payer could costlessly distinguish and pay the appropriate prices for each indication. Such 
differential pricing within product may become increasingly important and feasible as drugs 
become more “personalized” based on patient biomarkers and data systems are improved to 
provide the necessary information at reasonable administrative cost.  
Our approach to value-based pricing is similar to that proposed by Claxton et al. [22], 
with important differences. First, because our approach is grounded in overall utility 
maximization, the payer’s ICER threshold reflects consumers’ willingness-to-pay for health gain 
and the health care system is assumed to be funded accordingly. By contrast, Claxton et al. take 
the health care budget as given, and the ICER threshold reflects the opportunity cost of current 
resource use. Second, our approach permits prices that transfer all surplus to manufacturers for 
the duration of the patent to achieve dynamic efficiency. This reflects our underlying assumption 
that patent terms are designed to achieve the optimal trade-off between current consumption and 
R&D for future consumption. Claxton et al. constrain manufacturers to a single price to retain 
some surplus for payers/consumers during the term of the patent. Implicitly, this assumes a 
higher preference for current vs. future consumption for pharmaceuticals compared to other areas 
of innovation that rely on patents. Third, they focus on a single country whereas our approach 
addresses efficient pricing and utilization in a global context.  
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We follow Garber et al. [4] and Lackdawalla and Sood [7] in using insurance to achieve 
efficiency, but our approach differs in important respects. In our value-based differential pricing 
(VBDP) approach, manufacturer prices are constrained indirectly, without the payer having to set 
a price. Given the payer’s ICER threshold, a drug’s maximum reimbursable price is constrained 
by its incremental effectiveness and cost savings, relative to current treatments. Constraining 
prices indirectly, through an ICER threshold, avoids having to assume that the payer can measure 
the counterfactual, pre-insurance, drug-specific consumer surplus for each drug [5-7]. This is 
“value-based pricing” in that such prices reward incremental effectiveness and cost savings, 
evaluated at societal willingness-to-pay for QALYs. Under our approach, in the single price case, 
price and use reflect second best optimal levels and assigns to the firm the full surplus at this 
level, to incentivize second best dynamic efficiency.  
We assume that eligibility for reimbursement/utilization of costly services is determined 
by the payer’s clinical criteria, rather than attempting to set patients’ cost-sharing at marginal 
cost and letting patients determine use, for three reasons. First, having a payer determine and 
measure the conceptually appropriate marginal cost is impractical and ignores effects on 
complementary or substitute medical services. Second, even if payers could set co-payments 
equal to the appropriate marginal cost, and patients accurately assessed their marginal benefit 
and chose first best utilization, paying uniform top-up payments for this level of use would not 
be optimal if raising funds is costly, such that second best principles apply. Third, this approach 
ignores the caps on patient cost sharing that exist in most public and private insurance plans, to 
provide financial protection. Patients who use costly and/or chronic medications spend beyond 
the cost-sharing stop-loss, at which point all care is free and cost-sharing cannot constrain prices 
or use. We therefore assume that co-payments are set at modest levels to deter excess demand 
and raise funds, and that payers determine eligibility for reimbursed utilization based on whether 
the patient’s expected benefit meets the ICER threshold. This conforms to actual practice in most 
national insurance systems, where payers define eligibility for costly technologies and only 
reimburse for patients with approved indications. Similarly, in the US, most private and public 
health plans have cost-sharing limits such that nominal co-payments rarely determine use of 
costly products. Patients without coverage or without stop-loss protection are usually eligible for 
manufacturers’ cost-sharing coupons or patient assistance programs. Thus actual use is 
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constrained mainly by payers’ prior authorization and step therapy protocols that limit 
reimbursement for expensive drugs to patients that meet clinical criteria [20].  
 
Practical Issues in Defining ICER Thresholds  
 
 Patient Heterogeneity  If a payer applies a single threshold ICER across all 
individuals, this ICER may differ from the willingness-to-pay for medical care of some 
individuals. In a world of perfect information, costless insurance and no altruistic concern for the 
poor, this would violate Pareto efficiency. Under more realistic assumptions, any insurance 
imposes some restrictions on individual choice. Presumably, citizens choose to establish national 
health insurance or join private insurance plans because the expected benefits, in financial 
protection and improved equity, exceed the utility cost of constrained choice. In such contexts, 
setting rules in ways that aim to reflect ex ante consumer preferences is likely to be superior to 
strategies that ignore them. How best to elicit such preferences is an important issue for future 
research.  
Moreover, there are ways of accommodating consumer heterogeneity, even in universal 
insurance systems with a single payer or competing insurers, to provide for both “voice” and 
“exit.” For example, in a pluralist system of competing insurers such as the US, different health 
plans could choose  different ICER thresholds, implying different levels of patient access and 
different drug prices, implemented through rebates as already occurs. Individuals would choose a 
health plan that best reflects their preferences and willingness-to-pay for health. Such differences 
could be constrained by minimum universal coverage requirements and subsidies, as proposed 
by the Affordable Care Act of 2010.   
Private and public payers, in single payer or competing payer systems, could also vary ICERs 
by health condition to address social preferences across conditions. An illustrative example is 
given by the UK NICE. Although NICE has gone further towards uniformity than most payers 
by publishing an acceptable range for cost per QALY, exceptions exist. NICE has also 
introduced an “end of life” ICER threshold, reflecting perceptions that society’s willingness-to-
pay for health increases with disease severity. Further, in any insurance plan, patients who are 
deemed ineligible for coverage of a given product could be permitted to pay out of pocket. Thus 
the potential welfare losses associated with use of uniform ICERs across patients with 
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heterogeneous preferences could be minimized, subject to any requirements for universal 
coverage.   
 
Measuring Costs and Effectiveness  Measurement of costs and effectiveness raises many 
practical challenges, both conceptual (which costs should be included?) and empirical (how to 
estimate uncertain long term benefits?), and implementation is unlikely to be perfect. Addressing 
these issues is critical but beyond the scope of this paper.  
 
Price Differences Across Countries  
Our framework has implications for determining appropriate price differences across 
countries to achieve static and dynamic efficiency, at least for countries with universal insurance 
coverage. In such countries, if each public and private payer defines its ICER threshold 
unilaterally, based on its citizens’ willingness-to-pay for health gain; manufacturers are permitted 
to price up to that threshold; and payers manage utilisation to reimburse for cost-effective use at 
that price, then the resulting prices and utilization should be consistent with second best static 
and dynamic efficiency both within each country and across countries.  
To consider how willingness-to-pay – and therefore ICER thresholds and VBDP prices --  
might vary with income across countries, assume initially that incremental effectiveness, 
discount factors and quality of life adjusters are invariant with income and that each country 
ignores the potential effects of its ICER choice on its prices and the global supply of new drugs. 
For this simplest case, differentiating the right hand side of eq. 3 with respect to income yields:  
 
ௗ
ௗ௒ ቄ	
௩
௎బᇲቅ =  
ௗூ஼ாோ∗
ௗ௒ ൌ 1 െ	
ாೆᇲೊ
ாೆೊ   (4)  
 
The term ܧ௎௒ measures the elasticity of utility with respect to income (ܷ݀ ܻ݀ൗ ∙ ܻ ܷൗ ) and is 
expected to be positive, ܧ௎௒ ൐0. ܧ௎ᇲ௒  is the elasticity of marginal utility with respect to income 
(ܷ݀ᇱ ܻ݀ൗ ∙ ܻ ܷᇱൗ ) and is also known as relative risk-aversion. If ܧ௎ᇲ௒ ൏ 0, individuals are risk-
averse and the optimal ICER rises more than in proportion to income.  If ܧ௎ᇲ௒ ൌ 0, individuals 
are risk neutral and the optimal ICER rises in proportion to income.  Thus if two countries differ 
in per capita income but otherwise have similar preferences, our model suggests willingness-to-
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pay for medical care and the resulting preferred ICER and level of prices and access will likely 
be higher in the higher income country but the precise relationship to income cannot be predicted 
from theory.  
 
Incentives to Free Ride A necessary condition for VBDP to be efficient is that each 
country’s ICER(s) should express its citizens’ true preferences, rather than attempting to free ride 
on other countries’ willingness-to-pay for the global joint costs of R&D. In practice, a country 
that accounts for a small share of global drug sales might recognize that setting an artificially low 
ICER threshold below its true willingness-to-pay reduces the prices that it pays for drugs with 
only modest effect on its access to drugs or on global incentives for R&D to develop new drugs.  
Such free riding incentives exist in any approach to setting pharmaceutical prices and are not 
unique to VBDP.  Free riding may be mitigated under VBDP to the extent that this approach can 
be applied to all medical technologies, not just drugs, and hence might be less prone to free 
riding than alternative approaches targeted only at drug price regulation. Further, choosing an 
ICER threshold below citizens’ true willingness-to-pay may constrain access and utilization as 
well as prices to suboptimal levels.  
In practice, countries with universal insurance increasingly use cost-effectiveness as one tool 
in their regulatory systems for drugs and some other medical technologies. To the extent that 
these systems reflect country-specific willingness to pay for medical care, current regulatory 
structures may approximate the VBDP approach. However, there is also growing use of external 
price referencing for pharmaceuticals, which may imply strategic behavior rather than unilateral 
choice. In particular, when a high per capita income country references its prices to those paid by 
lower income per capita countries, this suggests free riding and suboptimal price differentials, 
rather than country-specific pricing reflected citizens’ true preferences, as required for VBDP 
and for dynamic efficiency generally.  
   
IV. Self-pay markets 
Middle and low income countries (MLICs) that lack comprehensive insurance avoid the 
distorting effect of insurance on manufacturer prices but also lack the financial protection 
insurance provides. This affects ability to pay especially for lower income citizens. Assuming 
that countries lacking universal insurance coverage are self-pay markets, in theory the GP model 
 15
should apply directly: patients’ self-pay demand reflects willingness-to-pay for expected 
incremental QALY benefits, provided that patients accurately perceive product quality. If certain 
other conditions are met – specifically, that: 1. Manufacturers of on-patent products can price-
discriminate between countries, and 2. generic markets are price-competitive – then prices and 
utilization in these self-pay markets should also meet conditions for second best static and 
dynamic efficiency, consistent with VBDP. Affordability for lower income patients also requires 
manufacturer ability to segment and price discriminate roughly based on income within the 
country. 
 In practice, theory suggests and empirical evidence confirms that these conditions for 
second best static and dynamic efficiency in self-pay markets are violated in many MLICs. First, 
highly skewed income distributions create incentives for single-price monopolists to charge 
prices that are high, relative to average per capita income [1], and price-discrimination between 
income groups within countries is generally not feasible [2]. Second, generic quality is uncertain 
in most MLICs because generics are not required to meet regulatory standards of bioequivalence 
to the originator.  Uncertain product quality leads to competition focused on brand, rather than 
price. Evidence confirms that prices of both on-patent and generic drugs are higher, relative to 
per capita income, in many MLICs compared to industrialized countries, and price competition  
is weak [2].  This suggests that achieving VBDP in these self-pay markets would thus require 
regulatory systems to assure product quality and purchasing mechanisms that facilitate price 
competition between drugs and possibly price discrimination between market sectors based on 
income. One such approach for HIV, TB and malaria drugs is described in [2]. Design of 
mechanisms for a broader range of drugs is an important topic but beyond the scope of this 
paper.  
 
V. Relation between Value-based Differential Prices and Ramsey Pricing  
We have argued that if certain conditions are met -- specifically, that each country with 
comprehensive insurance chooses its ICER threshold(s) based on preferences of a representative 
citizen; firms set price(s) in each country to meet its ICER threshold(s); and payers assure access 
for all patients for whom the drug is cost-effective at these prices – then prices and utilization 
should approximate second best static and dynamic efficiency locally and globally, at least for 
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these countries. These prices would vary across countries with (but not necessarily in proportion 
to) per capita income. 
As discussed earlier, Ramsey pricing has been proposed [9, 10] as an alternative 
theoretical framework for determining optimal pharmaceutical price differentials between 
countries. The question thus arises whether/how VBDP price differentials differ from ROP 
differentials?  
Ramsey pricing is designed to address the problem: Given an exogenously determined 
investment that serves multiple users, what prices to these users would maximize social welfare, 
subject to yielding a normal return on the investment (ROI). The ROP solution sets price 
differentials above marginal cost to minimize welfare loss from consumption below first best 
levels, subject to covering the firm’s fixed cost. Assuming constant marginal cost and a single 
price per country, this implies prices vary across countries inversely with price elasticity of 
demand.  
Certain differences between ROP and VBDP are implied by their respective objective 
functions. ROP prices are theoretically designed to yield a normal ROI on a fixed investment, 
rather than to transfer the entire surplus from an investment innovation to producers, as required 
for dynamic efficiency and approximated by our VBDP approach. Moreover, the maximand in 
the standard ROP set up is one period consumer surplus, with no measure of future utility from 
current consumption and no explicit consumer budget constraint. By contrast, the maximand in 
the VBDP approach incorporates the effect of current medical utilization on expected lifetime 
utility, subject to a lifetime budget constraint. The ROP approach solves for price differentials to 
achieve a target return on fixed past investment, whereas the VBDP approach sets price levels 
(and differentials by implication) to transfer whatever surplus results from the innovation, valued 
at each country’s willingness-to-pay, to incentivize future R&D. Thus both VBDP and ROP are 
designed to achieve second best static efficiency, but only VBDP is also designed to achieve 
dynamic efficiency.    
 Inspection of both models suggests that optimal prices will vary across countries with 
income, but precise proportionality is not necessarily implied by either, and the precise 
relationship could differ. In the case of ROP, prices vary across markets inversely with E, the 
uncompensated price elasticity of demand (absolute value). From the Slutsky equation (using 
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absolute values), the uncompensated price elasticity for good ݆ (Ej) is equal to the compensated 
price elasticity ௝߳ plus the income elasticity of demand ߟ௝ times the income share of j: 
 
ܧ௝ ൌ ௝߳	 ൅ 	ݏ௝η௝         (5) 
 
Plausible assumptions are that ௝߳ is invariant with income but η௝ increases with income. 
Differentiating (5) with respect to income yields:  
 
ௗாೕ
ௗ௒ ൌ 	
ௗ௦ೕ
ௗ௒ η௝ ൅
ௗ஗ೕ	
ௗ௒ ݏ௝  (6) 
 
The share s is positive and, for a given price, decreases with income, cet. par. The first term on 
the right is therefore negative. The second term is uncertain. The overall expression is likely to 
be negative i.e. price elasticity decreases with income, unless the last term is large and positive. 
Thus under plausible assumptions E varies inversely with income, and therefore ROPs vary 
directly with income across countries. Comparing eqs. 4 and 6, the cross-national relationship 
between prices and income is not necessarily the same under ROP and VBDP, due to differences 
in model specification, including how health enters the objective function of the respective 
models.  In the ROP formulation, income affects prices via the income elasticity of demand for 
health, whereas in the VBDP model the effect of income depends on the elasticity of marginal 
utility of non-medical consumption. Obviously, there is no unique a priori correct way to 
incorporate health into utility functions and hence no determinate relationship between optimal 
drug prices and income across countries. However, both the ROP and VBDP approaches suggest 
that optimal prices will plausibly increase with income.  
In our characterization of self-pay markets we have argued [9,10] that since profit 
maximizing price discrimination leads to the same relative prices (inversely related to demand 
elasticities) as ROP prices, market incentives should lead unregulated price discriminating firms 
to set optimal price relativities across markets, provided they can segment markets between and 
within countries, based on demand elasticities. Absolute price levels might be constrained to 
yield only a normal ROI by competitive entry to achieve a monopolistically competitive 
equilibrium. Whether actual cross-national price differentials in self-pay MLIC markets 
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approximate ROP differentials cannot be determined because true demand elasticities and 
marginal costs are not readily observable. However, observed elasticities of prices with respect 
to average per capita income are close to zero for a sample of MLICs [2], which seems 
inconsistent with optimal differentials under either ROP or VBDP prices. As discussed above, 
characteristics of many MLICs that violate necessary conditions for optimal differentials include: 
skewed income distributions combined with a lack of within-country price-discrimination; 
product quality uncertainty for generics and copy products due to lack of enforcement of 
regulatory quality standards; and competition based on brand, not price [2]. These plausibly 
explain the divergence of observed elasticities of prices with respect to average per capita 
income from those predicted by both VBDP and ROP.  
 
Conclusions 
An increasing number of countries use a range of regulatory systems for setting 
pharmaceutical prices, but these regulatory approaches are generally ad hoc and not solidly 
grounded in economics. We show that for countries with universal insurance, if each country 
unilaterally and non-strategically sets an ICER threshold based on willingness-to-pay for health 
gain and permits firms to price up to the ICER, while the payer assures reimbursement for all 
patients whose expected health gain meets the ICER effectiveness threshold, the resulting prices 
and utilization would be “valued-based” and yield second best static and dynamic efficiency 
within and across countries. In other words, the resulting price levels and differentials would be 
appropriate across countries to achieve second best optimal global incentives for utilization and 
innovation. If it is feasible, in addition, for payers to implement price differentials between 
patient subgroups/indications to reflect their differences in incremental effectiveness, then VBDP 
would approximate first best static and dynamic efficiency. Such value-based prices are likely to 
vary cross-nationally with per capita income and be broadly consistent with Ramsey Optimal 
Prices but the precise relationship with per capita income is indeterminate a priori.  
Countries lacking comprehensive insurance avoid the distorting effect of insurance on 
manufacturer prices, but also lack insurance’s role in financial protection and assuring 
affordability of medical care, regardless of income. In such self-pay markets, unregulated price 
discrimination by firms could in theory lead to Ramsey optimal price differentials, which may 
approximate second best static and dynamic efficiency, provided certain necessary conditions are 
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met. These include that consumers are well-informed about product quality and firms can 
segment and price-discriminate within as well as between countries, to reflect the skewness of 
income within many MLICs.  
To the extent that countries with universal insurance use cost-effectiveness as a criterion 
for reimbursement and these systems reflect country-specific willingness to pay for medical care, 
current regulatory structures for pharmaceuticals may approximate the value-based differential 
pricing we model, thereby making efficient use of existing drugs and sending appropriate signals 
to the global pharmaceutical industry about future investment in R&D.  However, other features 
of regulatory systems are inconsistent with the necessary conditions for efficiency outlined here. 
Notably there is considerable use of external price referencing which, by seeking to link prices 
across countries that do not have similar levels of income per capita and preferences over health 
and other goods, undermines the condition that each country’s ICER(s) express its citizens’ true 
preferences and willingness-to-pay for health gain. In addition, the requirement for first best 
static and dynamic efficiency – differential pricing by indication and patient subgroup – is 
currently not feasible for most drugs in most health systems. This may change with the arrival of 
new biological drugs with multiple indications of different value and increased availability of 
biomarkers and diagnostics to predict heterogeneity of patient response. If data and information 
systems also permit differentiated reimbursement, this would permit an ICER-based system to 
accommodate differential pricing across indications, to accommodate differential value and 
move towards first best. 
 Key assumptions for self-pay markets to deliver efficient prices are not present in 
MLICs, notably drug quality is often uncertain, price competition works poorly and 
segmentation and price discrimination within countries is often infeasible. These factors 
contribute to price levels that appear inconsistent with static and dynamic efficiency. Designing 
systems in MLICs to deliver consistent quality, facilitate price competition and increase 
affordability while preserving some contribution to and incentives for R&D are important issues 
for future research.  
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